VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
January 09, 2023 16:01 ET
|
VYNE Therapeutics Inc.
First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November Topline data expected in 1H 2023 BRIDGEWATER, N.J., Jan. ...
VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event
December 12, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
December 07, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
December 02, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
November 18, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
November 17, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 16:01 ET
|
VYNE Therapeutics Inc.
IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of...
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
August 12, 2022 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
August 10, 2022 08:32 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...